Table 6.

Adverse effects of medical therapy for thyroid eye disease

Drug (ref)	Frequency (%)	Severitya
		Minor (Grade 1)	Moderate (Grade 2)	Severe (Grade 3)	Life threatening (Grades 4–5)
IVGC (68, 72, 74)	≥10		Hyperglycemia
	5–9.9	GI symptoms		Infection
	1–4.9	Flushing	Hypertension depression Weight gain	Psychosis
	<1				Death, hepatic necrosis, myocardial infarction, stroke
OGC (66, 74)	≥10	GI symptoms	Hyperglycemia, weight gain, Cushingoid facies		Not reported
	5–9.9		Hypertension	Infection
	1–4.9		Depression
MMF (106)	1–4.9			Infection, hepatitis
MMF+GC (68)	≥10	GI symptoms		Infection
	5–9.9
	1–4.9		Sleep disorder
RTX (53, 67, 100)	≥10		Infusion reaction (nonsevere)
	5–9.9	GI symptoms		Transient visual lossb
	1–4.9			Vasculitis
	<1				Infusion reaction (severe)
TEP (89, 90, 91)	≥10	GI symptoms, myalgias, alopecia, fatigue	Hyperglycemia	Hearing loss, inflammatory bowel disease aggravation
	5–9.9	Dry skin	Taste disturbance
	1–4.9				Cerebral hemorrhage
TCZ (84, 111, 112)	≥10	Fatigue	Hyperlipidemia, neutropenia	Infection
	5–9.9	Pruritus		Hepatitis
	1–4.9		Thrombocytopenia Transaminase elevation
	<1				Anaphylaxis Bowel perforationc

^aNational Cancer Institute Common Terminology Criteria for Adverse Events (https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf). Grade 1: Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated. Grade 2: Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4: Life-threatening consequences, urgent intervention indicated. Grade 5: Death related to adverse event.

^bBelieved related to cytokine release syndrome.

^cObserved in other studies (not described in TED studies).